Evidence suggests that eccDNA levels rise in response to intensive insulin treatment among T2D patients, particularly for eccDNA derived from repetitive DNA, with differential gene presence observed between pre- and post-treatment, mainly in inflammation and metabolic genes [35]. The gene discussed is INS; the disease is type 2 diabetes mellitus.